Drilldown: Medicines
Medicines > classes 
:
Phenethylamine or
[[:Category:Atypical neuroleptics|Atypical neuroleptic (second-generation)]]
:
Phenethylamine or
[[:Category:Atypical neuroleptics|Atypical neuroleptic (second-generation)]] Use the filters below to narrow your results.
generic:
25B-NBOH (1) ·
25B-NBOMe (1) ·
25C-NBOH (1) ·
25C-NBOMe (1) ·
25I-NBOH (1) ·
25I-NBOMe (1) ·
25N-NBOMe (1) ·
2C-B (1) ·
2C-B-FLY (1) ·
2C-C (1) ·
2C-D (1) ·
2C-E (1) ·
2C-I (1) ·
2C-P (1) ·
2C-T-2 (1) ·
2C-T-7 (1) ·
Allylescaline (1) ·
Bromo-DragonFLY (1) ·
DOB (1) ·
DOC (1) ·
DOI (1) ·
DOM (1) ·
Escaline (1) ·
Methallylescaline (1) ·
Olanzapine (1) ·
Proscaline (1) ·
Risperidone (1) ·
TMA-2 (1)
brand:
None (25) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Risperdal (oral), Risperdal M-Tab (ODT), Risperdal Consta (biweekly IM LAI), Perseris (monthly SC LAI), Uzedy (monthly/bimonthly SC LAI), Rykindo (biweekly IM LAI) (1) ·
Zyprexa (oral, IM acute), Zyprexa Zydis (ODT), Zyprexa Relprevv (LAI), Lybalvi (with samidorphan) (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Very potent 5-HT2A agonist; long duration (1)
uses:
None (26) ·
'"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)
starting dose:
None (26) ·
Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap (1) ·
Schizophrenia / mania: 1 mg PO BID, titrate to 4-8 mg/day. Pediatric autism irritability: 0.25-0.5 mg/day, weight-titrated. Consta LAI: 25 mg IM every 2 weeks after oral overlap (1)
preparations:
None (26) ·
Tablets 0.25, 0.5, 1, 2, 3, 4 mg; M-Tab ODT 0.5, 1, 2, 3, 4 mg; oral solution 1 mg/mL; Consta LAI 12.5, 25, 37.5, 50 mg; Perseris SC LAI 90, 120 mg monthly (1) ·
Tablets 2.5, 5, 7.5, 10, 15, 20 mg; ODT (Zydis) 5, 10, 15, 20 mg; acute IM injection 10 mg/vial; Relprevv LAI 210, 300, 405 mg vials (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (25) ·
Not established (1) ·
Signal for gestational diabetes and metabolic syndrome with maternal exposure; the metabolic load can be substantial during pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 28 results in range #1 to #28.